Literature DB >> 32463094

Adjuvant treatment of endometrial cancer today.

Yoichi Aoki1, Hiroyuki Kanao1, Xipeng Wang2, Mayu Yunokawa1, Kohei Omatsu1, Atsushi Fusegi1,3, Nobuhiro Takeshima1.   

Abstract

Endometrial cancer frequently occurs in post-menopausal women, and the endometrium is a well-known site of cancer affecting women. Endometrial cancer is found with genital bleeding and often at an early stage. However, there are some risks of recurrence after hysterectomy. As a medical treatment after the diagnosis of endometrial cancer, appropriate adjuvant therapy is considered to lead to a decrease in the rate of recurrence and improvement of prognosis according to the determination of the cancer stage from the surgical and histopathological results. In this review, we describe post-operative adjuvant therapy administered for endometrial cancer and advanced disease, focusing on chemotherapy, radiation therapy and the combination of both. These treatments are divided according to the risk of recurrence as based primarily on the reported evidence.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.

Entities:  

Keywords:  adjuvant therapy; chemotherapy; endometrial cancer

Year:  2020        PMID: 32463094     DOI: 10.1093/jjco/hyaa071

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  11 in total

1.  Exploration of the Effect and Potential Mechanism of Echinacoside Against Endometrial Cancer Based on Network Pharmacology and in vitro Experimental Verification.

Authors:  Wan Shu; Ziwei Wang; Rong Zhao; Rui Shi; Jun Zhang; Wei Zhang; Hongbo Wang
Journal:  Drug Des Devel Ther       Date:  2022-06-16       Impact factor: 4.319

2.  Network Pharmacology-Based and Molecular Docking Analysis of Resveratrol's Pharmacological Effects on Type I Endometrial Cancer.

Authors:  Zixing Zhong; Xin Guo; Yanmei Zheng
Journal:  Anticancer Agents Med Chem       Date:  2022       Impact factor: 2.527

3.  CMBs carrying PTX and CRISPR/Cas9 targeting C‑erbB‑2 plasmids interfere with endometrial cancer cells.

Authors:  Siyuan Peng; Junhong Cai; Shan Bao
Journal:  Mol Med Rep       Date:  2021-09-30       Impact factor: 2.952

4.  Circular RNA hsa_circ_0011324 is involved in endometrial cancer progression and the evolution of its mechanism.

Authors:  Dajiang Liu; Xuehan Bi; Yongxiu Yang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches.

Authors:  Zsuzsanna Szabo; Eva Juhasz; Andrew V Schally; Balazs Dezso; Sandor Huga; Zoltan Hernadi; Gabor Halmos; Csongor Kiss
Journal:  Molecules       Date:  2022-04-21       Impact factor: 4.411

6.  The IFN-γ-related long non-coding RNA signature predicts prognosis and indicates immune microenvironment infiltration in uterine corpus endometrial carcinoma.

Authors:  Chunyan Gu; Chen Lin; Zheng Zhu; Li Hu; Fengxu Wang; Xuehai Wang; Junpu Ruan; Xinyuan Zhao; Sen Huang
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

7.  Aberrant TRPC1 expression reflects stromal cervical invasion, lymphovascular invasion, elevated FIGO stage, and poor survival in resectable endometrial carcinoma patients.

Authors:  Yi Wang; Chun Zhang
Journal:  J Clin Lab Anal       Date:  2022-06-26       Impact factor: 3.124

8.  GPX4 suppresses ferroptosis to promote malignant progression of endometrial carcinoma via transcriptional activation by ELK1.

Authors:  Sitian Wei; Zhicheng Yu; Rui Shi; Lanfen An; Qi Zhang; Qian Zhang; Tangansu Zhang; Jun Zhang; Hongbo Wang
Journal:  BMC Cancer       Date:  2022-08-12       Impact factor: 4.638

9.  Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma.

Authors:  Sitian Wei; Jun Zhang; Rui Shi; Zhicheng Yu; Xingwei Chen; Hongbo Wang
Journal:  Front Oncol       Date:  2022-09-07       Impact factor: 5.738

10.  MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.

Authors:  Nan Lu; Jinhui Liu; Chengjian Ji; Yichun Wang; Zhipeng Wu; Shuning Yuan; Yan Xing; Feiyang Diao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.